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S U M M A R Y
Objectives: In the United Arab Emirates (UAE), many vaccine-preventable diseases are notiﬁable and are
often reported despite high estimated immunization coverage. The serological assessment of immunity
against these infections (serosurveillance) complements disease surveillance (notiﬁcation). This study
aimed to assess the yet unmeasured serological immunities to nine vaccine-preventable infections
among vaccinated Emirati children.
Methods: This cross-sectional study involved children who attended the Well-Child Care Programme of
the Ambulatory Healthcare Services (Al-Ain, UAE) between July 2014 and September 2015. Serological
testing was performed in 227 Emirati children (49% females); subjects were aged (mean  standard
deviation) 45  14 months (median 43, range 23–71 months).
Results: The seroprevalence rates varied markedly among the studied vaccine-preventable diseases,
ranging from 39.2% (pertussis) to 98.3% (rubella). Other high seroprevalence rates were noted for
measles (98.2%) and poliovirus (92%). The seroprevalence rate for mumps was 82.8%, for varicella was
68.3%, for diphtheria was 86.4%, for tetanus was 89.9%, and for Haemophilus inﬂuenzae type B was 84.1%.
Conclusions: A large number of the studied children had low seroprevalence rates against pertussis,
varicella, and mumps. Studies are needed to explore whether modifying the national immunization
programme could improve these low seroprevalence estimates.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Despite the advances in vaccine preparations and scheduling,
many children are still susceptible to common communicable
diseases. The Health Authority of Abu Dhabi, United Arab Emirates
(UAE) was notiﬁed of 268 cases of chickenpox, 39 cases of measles,
20 cases of mumps, and four cases of pertussis in children 4 years
of age in the ﬁrst two quarters of 2015; unfortunately, the
vaccination status of these children was not reported.1 Disease
surveillance (notiﬁcation data) is central to detecting outbreaks
and providing timely information on the trends of vaccine-
preventable diseases. However, such data may be incomplete and
biased by variations in case deﬁnitions and classiﬁcations.
Serosurveillance data, on the other hand, measures immunity
that results from vaccination or past infection. These data are very* Corresponding author. Tel.: +9-713-713-7411; fax: +9-713-767-2022.
E-mail address: alsuwaidia@uaeu.ac.ae (A.R. Alsuwaidi).
http://dx.doi.org/10.1016/j.ijid.2016.07.012
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).useful for mathematical modelling to determine the potential for
future outbreaks and the need for public health interventions such
as modiﬁcations to the vaccination programmes or conducting
vaccination campaigns.2
Immune responses to vaccines are inﬂuenced by several factors,
including genetic predisposition. Inherited differences in molecules
involved in immune signalling have been suggested to explain the
variation in response to vaccines among various populations.3
Other potential factors include nutritional status, congenital or
acquired defects in immunity, inter-current infection, and vaccine-
related variables (e.g., preparation, interactions, and administration
sequence).4 Individuals who are immune to an infectious disease
are not only protected themselves, but also do not spread the
disease. When a critical proportion of the population becomes
immune, the herd immunity threshold is reached, halting disease
transmission in the population.5 For this, vaccination coverage
above 95% among susceptible groups is necessary, in addition to the
need for a surveillance system that would identify the groups at risk
of contracting these vaccine-preventable infections. An effectiveciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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of individuals with positive serological immunity, reaching or
exceeding the herd immunity threshold, which ranges from 66%
(Haemophilus inﬂuenzae type B (Hib)) to 83% (measles), for each
vaccine-preventable infection.5,6
The UAE has adopted the World Health Organization (WHO)
Expanded Programme on Immunization (EPI) since 1978. The UAE-
EPI includes childhood, school, adult, Hajj and Umrah, and traveller
vaccines. Childhood vaccine coverage was estimated at 99% in
2014.7 In brief, since 2011, a hexavalent vaccine (diphtheria–
tetanus–acellular pertussis (DTaP), hepatitis B virus (HBV),
inactivated poliovirus (IPV), and Hib) has been given at 2 and
4 months, and a pentavalent vaccine (DTaP–HBV–Hib) and oral
poliovirus vaccine at 6 months. The tetravalent (DTaP–Hib) and
oral poliovirus vaccines are given at 18 months. Tdap (tetanus,
diphtheria, and pertussis) and oral poliovirus are given in grade
11. The measles–mumps–rubella (MMR) vaccine is given in two
doses at 12 months and in grade 1. In February 2015, the Health
Authority of Abu Dhabi updated the immunization schedule and
introduced a second MMR dose at 18 months; the dose given in
grade 1 will continue until the children who received two doses at
12 and 18 months are enrolled in grade 1. Varicella vaccine is given
at 12 months and in grade 1. Oral poliovirus vaccine is also given in
grade 1. Rubella and human papillomavirus vaccines are given to
females only in grade 9 and 11, respectively. The varicella vaccine
was added to the childhood vaccines in 2010 and to the school
vaccines (grade 1) in 2012. Pneumococcal conjugate vaccine is
given at 2, 4, 6, and 18 months. Rotavirus vaccine was added in
2013 at 2 months and 4 months. In addition, several childhood
campaigns have been conducted in the region (e.g., the oral
poliovirus vaccine campaign in January 2015).8
As no serosurveillance data are available in the UAE for vaccine-
preventable diseases despite the continuing occurrence of some of
these infections, this study was undertaken to assess the
prevalence of antibodies against these diseases among vaccinated
Emirati children.
2. Methods
2.1. Study participants and data collection
This cross-sectional study involved an unselected cohort of
231 children who attended the Well-Child Care Programme of the
Ambulatory Healthcare Services (Al-Ain, Abu Dhabi) between July
2014 and September 2015. This programme (birth to 6 years of
age) was ﬁrst established in the Emirate of Abu Dhabi in March
2013. The programme delivers preventive care as set by the Health
Authority of Abu Dhabi policies and international guidelines. It
provides care at 34 centres in the entire Emirate of Abu Dhabi,
where 70% of patients are Emirati. A primary aim of this
programme is to enhance culturally relevant preventive measures
that include clinical assessment, immunization, nutrition, preven-
tive measures, and screening. No speciﬁc sampling method was
used, as all children presenting to these services during the study
period and who were eligible for enrolment in the study were
included if the parents consented.
Inclusion criteria were: (1) children 23 months to 6 years of age,
and (2) an up-to-date immunization status. Exclusion criteria were
acute or chronic medical illnesses, and regular medications other
than acetaminophen or ibuprofen. The immunization status was
veriﬁed by reviewing the clinic vaccination logbooks, individual
patient immunization cards, and electronic records. No history of
prior infection with a vaccine-preventable illness was collected.
Blood was collected and processed to measure the immune
responses to nine selected vaccine-preventable diseases: diphthe-
ria, tetanus, pertussis, poliovirus, Hib, measles, mumps, rubella,and varicella. All negative or equivocal results were repeated at
least once for conﬁrmation.
2.2. Laboratory testing
An ELISA was used to measure IgG antibody titres in the sera
of the participating children. All tests were performed and
interpreted according to the manufacturers’ instructions at a
single laboratory (the Central Reference Laboratory of the
Ambulatory Healthcare Services). Missing serology results were
due to inadequate serum volume to run all the tests in a blood
sample.
For Hib, anti-polyribosylribitolphosphate IgG antibodies were
measured (RE56351; IBL International, Hamburg, Germany). A
failure to seroconvert following Hib vaccination was considered an
inability to react to this polysaccharide antigen. Immunoreactions
to non-typeable Haemophilus inﬂuenzae are not detected by this
test. Antibody concentrations <0.15 mg/ml corresponded to
insufﬁcient protection (negative), 0.15–1.0 mg/ml equivocal, and
>1.0 mg/ml sufﬁcient immunity (positive). For poliovirus
(RE56921; IBL International), titres <8 U/ml were negative, 8–
12 U/ml equivocal, and >12 U/ml positive. Antibodies against
Bordetella pertussis (BOPG0030), measles (MEAG0330), mumps
(MUMG0340), varicella zoster virus (VZV) (VZVG0490), Coryne-
bacterium diphtheriae toxin (CORG0090), Clostridium tetani toxin
(TETG0430), and rubella (RUBG0400) were measured using
NovaLisa test kits (Dietzenbach, Germany). For pertussis, measles,
mumps, and VZV, titres <9 NTU (NovaTec units) were negative, 9–
11 NTU equivocal, and >11 NTU positive. For diphtheria and
tetanus, titres <0.01 IU/ml were negative, 0.0–0.1 IU/ml equivocal,
and >0.1 IU/ml positive. For rubella, titres <10 IU/ml were
considered negative, 10–15 IU/ml equivocal, and >15 IU/ml
positive.
2.3. Statistical analysis
The collected data were entered and analysed using IBM SPSS
Statistics version 20.0 (IBM Corp., Armonk, NY, USA). For the
purpose of the study, all positive and negative serology results
excluded the equivocal or grey zone results. A descriptive analysis
was performed on the percentage of children with positive
serology results for each vaccine and was calculated with 95%
conﬁdence intervals (CI). These were also calculated across four
age bands (23–35 months, 36–47 months, 48–59 months, and 60–
72 months). The number and percentage of children who had
negative serology to one or more vaccines was also calculated.
Pearson’s Chi-square test was used to compare the seropositivity
prevalence rates; if the expected frequency was less than ﬁve,
Fisher’s test was used instead. Statistical signiﬁcance was deﬁned
by a two-sided p-value of less than 0.05.
3. Results
Of the 231 children initially recruited, four were excluded (two
non-Emiratis who returned from living abroad and had never been
immunized, as stated by their parents, and two other children who
had insufﬁcient serum). The remaining 227 children (49% females)
were enrolled. Their age (mean  standard deviation) was
45  14 months (median 43, range 23–71 months).
The immunization history was veriﬁed in 217 children (217/
227, 95.6%) by reviewing the vaccination documentation (e.g.,
clinic logbooks, electronic records, and immunization cards). The
parents of 10/227 (4.4%) children could not be reached to conﬁrm
the immunization status.
The prevalence (mean; 95% CI) of positive serological immunity
varied markedly among the studied vaccines (Table 1). It was
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99.5) and lowest for varicella (68.3%; 61.8, 74.3) and pertussis
(39.2%; 32.8, 45.8). For individual vaccines, the prevalence of
positive serological immunity also varied with the age of the
children (Table 2).
For the 227 children, information on negative serology was
unavailable on all vaccine serology in 19 (8%). For the remaining
208 children, 43 (19%) had no seronegative results and 165 (81%)
were seronegative for at least one vaccine.
Seronegativity to only one vaccine occurred in 101 (44.5%)
children. This included 67 to pertussis (50% of all pertussis
seronegativities), 19 to varicella (26% of varicella seronegativities),
12 to mumps (31% of mumps seronegativities), two to diphtheria
(33% of diphtheria seronegativities), and only one to tetanus (11%
of tetanus seronegativities). The remaining 80 (35%) children had
seronegativity to more than one vaccine. Forty-three (20.6%)
children had seronegativity to two vaccines; 24 (55%) combina-
tions were pertussis plus varicella, nine (21%) were pertussis plus
mumps, and 10 (24%) were other combinations. Seventeen (8%)
children had seronegativity to three vaccines, and three (1.4%) had
seronegativity to four vaccines (One to pertussis, varicella, mumps
and measles; one to pertussis, varicella, mumps and rubella; and
one to pertussis, varicella, diphtheria and tetanus). One child (0.5%)
had seronegativity to ﬁve vaccines (diphtheria, pertussis, measles,
mumps, and varicella).
When negative serological immunity occurred to several
vaccines simultaneously in a child, pertussis, varicella, mumps,
tetanus, diphtheria, and measles were the most likely to be
involved. When the proportion of children with seronegativity to
one to four vaccines was compared amongst the age groups, it was
not statistically different (Chi-square test p = 0.72).
4. Discussion
This cross-sectional serosurveillance study estimated the level of
immunity against nine childhood vaccines in Emirati children. The
serological immunity rates below the recommended herd immuni-
ty threshold for pertussis, mumps, and varicella5 are consistent with
the observed endemics of pertussis, varicella, and mumps in the
region despite excellent childhood vaccination coverage.1 Reassur-
ingly, the serological immunity rates exceeded the herd immunity
threshold for measles, poliovirus, rubella, and Hib, mirroring the
near-absence of reported cases of these infections.5
Similar ﬁndings have been reported in other population-based
seroepidemiological studies. A report from Singapore described
serological immunity in children aged 1–17 years in 2008–2010;
immunity to measles was 83.1%, to mumps was 71.8%, and to
rubella was 88.5%.9 In another study involving Austrian childrenTable 1
Serological immunity against the nine studied vaccines in 227 fully vaccinated childre
Measles Mumps Rubella Diphtheria T
Positive 98.2
[95.5; 99.5]
(223)
82.8
[77.2; 87.4]
(188)
98.3
[95.5; 99.5]
(223)
86.4
[81.1; 90.5]
(196)
8
[
(
Equivocal 0
[NA]
(0)
0
[NA]
(0)
1.3
[0.2; 3.8]
(3)
7.9
[4.7; 12.2]
(18)
2
[
(
Negative 1.8
[0.4; 4.4]
(4)
17.2
[12.5; 22.7]
(39)
0.4
[0.1; 2.4]
(1)
2.6
[0.9; 5.6]
(6)
4
[
(
No data 0
[NA]
(0)
0
[NA]
(0)
0
[NA]
(0)
3.1
[1.2; 6.3]
(7)
3
[
(
NA, not applicable; Hib, Haemophilus inﬂuenzae type B.
a Values are presented as the percentage, [95% conﬁdence interval], and (n).aged 4–8 years, the immunity to tetanus was 96%, to measles was
90%, to diphtheria was 81%, to mumps was 72%, to rubella was 63%,
and to pertussis was 27%. The authors concluded that the low
levels of antibodies after vaccination against pertussis, rubella, and
mumps should be considered when recommending new vaccina-
tion schedules.10
In the present study, antibodies against measles virus were
found in 98.2% of the enrolled children, none had equivocal results,
and 1.8% of children had negative measles serology. As stated by the
World Health Organization (WHO), the proportion of susceptible
individuals should not exceed 5% for young adults above the age of
14 years in order to achieve an interruption in the transmission of
measles; the seropositivity rate of the studied children fulﬁls this
requirement.11 This is in contrast to an earlier observation of only
54% of Emirati medical students having positive measles antibodies.
The low measles seroprevalence rate among the medical students
cohort probably reﬂects early vaccination against measles with a
waning immune response produced by vaccination over time as
opposed to natural exposure to the virus.12,13
The overall prevalence of antibodies to rubella virus in this
study was 98.3%. The elimination of rubella and the prevention of
congenital rubella syndrome require that the percentage of
susceptible women of childbearing age is less than 5%, as
recommended by the WHO. The present study ﬁnding of 98.3%
of the studied children having antibodies to rubella virus is in line
with this requirement.14 However, it remains to be seen whether
this high rate is maintained in the older age groups.
Since the introduction of the MMR vaccine and despite
adequate vaccination coverage, cases of mumps are still reported
every year.1 This may be attributed to a loss of immunity against
the mumps virus over time as a result of reduced immunogenicity
induced by the mumps vaccine component of the MMR in relation
to the other two components (measles and rubella).13,15–17
However, immunity to the mumps virus is complex and
interpretation is complicated: although a high population sero-
positivity rate against the virus is an important factor in outbreak
prevention, the minimum protective titres are unknown, which
may therefore explain why seronegativity does not necessarily
equate with susceptibility.17,18
In this study, the total percentage of varicella (VZV) seropositiv-
ity was 68.3%, somewhat lower than in other reports, perhaps
because of the use of a different assay method for detecting anti-
VZV antibodies, in addition to the absence of a ‘gold standard’
method for detecting anti-VZV IgG.19 As equivocal results were nil
in this study, these differences in the seroprevalence rates cannot be
attributed to their exclusion from the positive, as in other reports.20
IgG antibodies to B. pertussis were detected in 39.2% of the
children and did not vary much with age. The young age of thena
etanus Pertussis Poliovirus Hib Varicella
9.9
85.1; 93.4]
204)
39.2
[32.8; 45.8]
(89)
92.0
[87.7; 95.2]
(209)
84.1
[78.7; 88.6]
(191)
68.3
[61.8; 74.3]
(155)
.2
0.7; 5.0]
5)
0
[NA]
(0)
4.0
[1.8; 7.3]
(9)
10.1
[6.5; 14.8]
(23)
0
[NA]
(0)
.0
1.8; 7.3]
9)
58.6
[51.8; 65.0]
(133)
4.0
[1.8; 7.3]
(9)
0
[NA]
(0)
31.7
[25.7; 38.2]
(72)
.9
1.8; 7.3]
9)
2.2
[0.7; 5.0]
(5)
0
[NA]
(0)
5.8
[3.0; 9.5]
(13)
0
[NA]
(0)
Table 2
Positive serology against the nine studied vaccines in 227 fully vaccinated childrena
Age in months Measles Mumps Rubella Diphtheria Tetanus Pertussis Poliovirus Hib Varicella
23–35 (n = 69) 98.5 (68)
[92.1; 99.9]
89.8 (62)
[80.2; 95.8]
98.5 (68)
[92.1; 99.9]
92.7 (64)
[83.9; 97.6]
89.8 (62)
[80.2; 95.8]
40.6 (28)
[28.9; 53.0]
88.4 (61)
[78.4; 94.8]
88.4 (61)
[78.4; 94.8]
71.0 (49)
[58.8; 81.3]
36–47 (n = 63) 96.3 (61)
[88.9; 99.6]
73.0 (46)
[60.3; 83.4]
98.4 (62)
[91.4; 99.9]
92.0 (58)
[82.4; 97.3]
89.9 (56)
[78.4; 95.4]
47.6 (30)
[34.8; 60.6]
93.6 (59)
[84.5; 98.2]
80.9 (51)
[69.0; 89.7]
74.6 (47)
[62.0; 84.7]
48–59 (n = 47) 100 (47)
[92.4; 100]
82.9 (39)
[69.1; 92.3]
97.8 (46)
[88.7; 99.9]
80.8 (38)
[66.7; 90.8]
89.3 (42)
[76.8; 96.4]
34.0 (16)
[20.8; 49.3]
91.5 (43)
[79.6; 97.6]
89.3 (42)
[76.8; 96.4]
59.6 (28)
[44.2; 73.6]
60–72 (n = 48) 97.9 (47)
[88.9; 99.9]
85.4 (41)
[72.2; 93.9]
97.9 (47)
[88.9; 99.9]
75.0 (36)
[60.4; 86.3]
91.6 (44)
[80.0; 97.7]
31.2 (15)
[18.6; 46.2]
95.8 (46)
[85.7; 99.4]
77.1 (37)
[62.6; 87.9]
64.6 (31)
[49.4; 77.8]
Equivocal or
unknown serology
(0) (0) (3) (25) (14) (5) (9) (36) (0)
Total (N = 227) 98.2 (223)
[95.5; 99.5]
82.2 (188)
[77.2; 87.4]
98.2 (223)
[95.5; 99.5]
86.3 (196)
[8.1; 90.5]
89.8 (204)
[85.1; 93.4]
39.2 (89)
[32.8; 45.8]
92.1 (209)
[87.7; 95.2]
84.4 (191)
[78.7; 88.6]
68.2 (155)
[61.7; 74.2]
Hib, Haemophilus inﬂuenzae type B.
a Values are presented as the percentage (number of children) and [95% conﬁdence interval].
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that this low rate could be related to differences by age in the
kinetics of pertussis toxin (PT) antibodies,21 or to the waning
immune response once the protection of primary vaccination has
been lost.22
The limitations of this study include the single nationality and
the narrow age band of the enrolled children attending the health
care system of a single city. As this cannot be considered a random
or a representative sample of the population of children, the
extrapolation of the study ﬁndings to other settings requires
careful consideration. Another limitation is that, as no history of
clinical infection with these vaccine-preventable diseases was
included in the survey, it is not possible to attribute the ﬁnding of a
positive serology result to the administration of the corresponding
vaccine or to the infection itself. Similarly, no clinical outcomes
were studied in order to correlate the ﬁndings with the protective
effect of these vaccines.
In summary, many fully vaccinated children may still be
susceptible to pertussis, varicella, and mumps, and this remains a
challenge to the immunization programme. National immuniza-
tion programmes need to be guided by population-based
serosurveillance studies before recommending the usage of more
immunogenic vaccines and/or improved schedules of administra-
tion. Immunizations tailored to particularly susceptible (e.g.,
boosters of varicella and measles vaccines for medical students)
or high-risk groups (boosters of pertussis vaccine for young
infants) may also be necessary. The efﬁcacy of such endeavours
with regard to carriage and herd immunity in the community will
require ongoing evaluation.
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